

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Currently amended) A method for the treatment of multiple sclerosis, comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of ~~riluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.
3. (Previously presented) The method of claim 2 wherein said pharmaceutical composition comprises a pharmaceutically effective carrier.
4. (Previously presented) The method of claim 2 wherein said pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of an additional agent.
5. (Previously presented) The method of claim 4 wherein said additional agent is selected from the group consisting of interferon beta-1a, interferon beta-1b, and copaxone.
6. (Currently amended) The method according to claim 2 wherein the amount of ~~riluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or the salt thereof administered to the patient is between about 10 and about 500 mg per day.
7. (Currently amended) The method of claim 6 wherein the amount of ~~riluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or the salt thereof administered to the patient is between about 50 and about 250 mg per day.

8. (Currently amended) A method for treating a patient suffering from multiple sclerosis comprising the step of administering a pharmaceutical composition comprising ~~fluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof in an amount effective to inhibit, minimize or delay the development of spinal cord atrophy associated with multiple sclerosis.
9. (Previously presented) The method of claim 8 wherein said pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of an additional agent selected from the group consisting of interferon beta-lb, interferon beta-la, and copaxone.
10. (Currently amended) A method for the treatment of a patient suffering from multiple sclerosis comprising the steps of administering to said patient:
 - a. a therapeutically effective amount of a pharmaceutical composition comprising ~~fluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof; and
 - b. a therapeutically effective amount of a pharmaceutical composition selected from the group consisting of interferon beta-lb, interferon beta-la, and copaxone.
11. (Currently amended) A method for the treatment of a patient suffering from primary progressive multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising ~~fluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.
12. (Previously presented) The method of claim 11 further comprising the administration of a therapeutically effective amount of interferon beta-lb, copaxone and interferon beta-la.
13. (Currently amended) A method for the treatment of a patient suffering from secondary-progressive multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising ~~fluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.

14. (Currently amended) A method for the treatment of a patient suffering from relapsing-remitting multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising ~~riluzole~~ 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.

15. (Currently amended) The method of claim 2, wherein the ~~riluzole in the~~ composition comprises 6-(trifluoromethoxy)-2-benzothiazolamine.

16. (Currently amended) The method of claim 2, wherein the ~~riluzole in the~~ composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

17. (Currently amended) The method of claim 8, wherein the ~~riluzole in the~~ composition comprises 6-(trifluoromethoxy)-2-benzothiazolamine.

18. (Currently amended) The method of claim 8, wherein the ~~riluzole in the~~ composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

19. (Currently amended) The method of claim 10, wherein the ~~riluzole in the~~ composition comprises 6-(trifluoromethoxy)-2-benzothiazolamine.

20. (Currently amended) The method of claim 10, wherein the ~~riluzole in the~~ composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

21. (Currently amended) The method of claim 11, wherein the ~~riluzole in the~~ composition comprises 6-(trifluoromethoxy)-2-benzothiazolamine.

22. (Currently amended) The method of claim 11, wherein the ~~riluzole in the~~ composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

23. (Currently amended) The method of claim 13, wherein the ~~riluzole in the~~ composition
[[is]] comprises 6-(trifluoromethoxy)-2-benzothiazolamine.

24. (Currently amended) The method of claim 13, wherein the ~~riluzole in the~~ composition
[[is]] comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

25. (Currently amended) The method of claim 14, wherein the ~~riluzole in the~~ composition
[[is]] comprises 6-(trifluoromethoxy)-2-benzothiazolamine.

26. (Currently amended) The method of claim 14, wherein the ~~riluzole in the~~ composition
[[is]] comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.